Cryofibrinogen, Qualitative
Use
Detect cryofibrinogen complexes in plasma1
Special Instructions
Not provided.
Limitations
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. Secondary cryofibrinogenemia has been associated with malignancy, diabetes mellitus, collagen vascular disease, and active infection. It may produce symptoms due to arterial occlusions, though many individuals with cryofibrinogenemia are asymptomatic. The test may also result in spontaneous bleeding due to clotting factor depletion.
Methodology
Other
Biomarkers
LOINC Codes
- 11043-7 - Cryofib Plas Ql
- 11043-7 - Cryofib Plas Ql
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
3 mL
Minimum Volume
1 mL
Container
Blue-top (sodium citrate) tube, lavender-top (EDTA) tube, or gray-top (sodium fluoride) tube
Collection Instructions
Specimen must be drawn in a prewarmed tube and kept at 37°C. Separate plasma from cells immediately, and transfer the plasma into a clean transport tube. Label transport tube 'Prewarmed.'
Storage Instructions
Maintain specimen at room temperature.
Causes for Rejection
Heparinized plasma; whole blood received
Other tests from different labs that may be relevant